What is Syneron Bio?
Syneron Bio is a biotechnology firm dedicated to the advancement of macrocyclic peptide therapies. Leveraging its proprietary Synova discovery platform, the company is building a robust pipeline targeting critical areas such as cancer and chronic conditions. Its operations are underpinned by a team possessing extensive expertise in drug development and data science, positioning it as a key player in the biopharmaceutical innovation landscape.
How much funding has Syneron Bio raised?
Syneron Bio has raised a total of $250M across 2 funding rounds:
Series A
$100M
Series B
$150M
Series A (2025): $100M with participation from Pfizer, AstraZeneca, 5Y Capital, Sinovation Ventures, and GREE Ventures
Series B (2026): $150M led by 5Y Capital, Lenovo Capital and Incubator Group (LCIG, True Light Capital, Qiming Venture Partners, BioTrack Capital, ADIA, AstraZeneca, and Decheng Capital
Key Investors in Syneron Bio
Pfizer
Pfizer is a global biopharmaceutical giant focused on researching, developing, and marketing medicines and vaccines across numerous therapeutic areas, including oncology and immunology.
AstraZeneca
AstraZeneca is a biopharmaceutical company specializing in the discovery, development, and commercialization of prescription medicines, with a strong emphasis on oncology and cardiovascular health.
5Y Capital
5Y Capital (formerly Morningside Venture Capital) is an investment firm that champions entrepreneurship, focusing on identifying and nurturing exceptional talent to foster societal progress.
What's next for Syneron Bio?
With substantial financial backing, Syneron Bio is poised for accelerated growth and the expansion of its therapeutic pipeline. The recent strategic investment suggests confidence from investors in the company's Synova platform and its potential to address significant unmet medical needs. Future endeavors will likely focus on advancing preclinical and clinical trials, further solidifying its market position, and potentially exploring strategic partnerships to broaden its reach and impact in the biopharmaceutical sector.
See full Syneron Bio company page
